Finding a Successor to AWP
This article was originally published in RPM Report
Executive Summary
The search is on for the next payment benchmark in pharma. AWP had a surprisingly long reign, but the end is at hand. The selection of a new standard will have a big impact on every part of the distribuiton chian.
You may also be interested in...
Bad Blood: The Amgen/J&J Feud Takes a Perilous Turn
The longstanding feud between Amgen and Johnson & Johnson is bubbling over into a battle of bundled rebates. The fight carries broad repercussions for the pricing of biopharmaceuticals. The dispute threatens to compromise the new ASP payment system under Medicare Part B before it really gets going. Industry observers threat that the next step may be more direct price controls.
Negotiating Price Negotiation: Why the Democrats Will Struggle to Pressure Part D Prices
The new Congress wants to make federal price negotiation under Medicare a reality. But it won't be easy. Big Pharma should expect plenty of interference from the Democrats in Part D, but it is hard to see a meaningful impact on prices in the near term.
Bad Blood: The Amgen/J&J Feud Takes a Perilous Turn
The longstanding feud between Amgen and Johnson & Johnson is bubbling over into a battle of bundled rebates. The fight carries broad repercussions for the pricing of biopharmaceuticals. The dispute threatens to compromise the new ASP payment system under Medicare Part B before it really gets going. Industry observers threat that the next step may be more direct price controls.